Year: 2013
Type: review
Abstract: Molecularly targeted agents promise to revolutionize therapeutics by reducing morbidity and mortality in patients with cancer.However, despite an urgent need for more effective anticancer compounds, current preclinical drug evaluations largely fail to satisfy the demand.New preclinical strategies, including the improvement of sophisticated mouse models and co-clinical study designs, are being used to augment the predictive value of animal-based translational cancer research.Here, we review the development of successful preclinical antineoplastic agents, their associated limitations, and alternative methods to predict clinical outcomes.Conflict of interest: Andrew L. Kung serves as a consultant to Novartis, Molecular Imaging, and Stemergie and has sponsored research agreements with
DOI: 10.1172/jci68340
Language: English
Subfield: Small Animals
Field: Veterinary
Domain: Health Sciences
Open Access status: bronze
Awards: MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer, G2018972360, In vivo analysis of EGFR mutant driven lung cancers responses to radiation therap, Therapeutic strategies for specific subsets of KRAS mutant lung cancers, G6586715722, G6756496003, Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma, In vivo murine models of metastasis for therapeutic testing, LKB1 tumor suppressor and human cancer, G982405977
OpenAlex ID: W2044406093